Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026PRNewsWire · Oct 15, 2026
Castle Biosciences Inc (CSTL) Shares Fall 4.8% -- What GF Score of 80 Tells InvestorsGuruFocus · Oct 12, 2026
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's EsophagusPRNewsWire · Oct 12, 2026
Castle Biosciences (NASDAQ:CSTL) Stock Price Down 6.1% Following Insider SellingDefense World · Oct 6, 2026
Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 1,034 Shares of StockDefense World · Oct 2, 2026
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical ManagementPRNewsWire · Sep 30, 2026Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | -$0.41 | -$0.07 | Beat |
| May 6, 2026 | -$0.49 | -$0.49 | Beat |
| Feb 26, 2026 | -$0.23 | -$0.08 | Beat |
| Nov 3, 2025 | -$0.34 | -$0.02 | Beat |
| Aug 4, 2025 | -$0.51 | $0.15 | Beat |
| May 5, 2025 | -$0.08 | -$0.90 | Miss |